The Pittsburgh Life Sciences Greenhouse is on a roll, having invested $800,000 in six regional life science companies this month.
“This latest round of investments marks a significant milestone for the PLSG,” says John W. Manzetti, PLSG President & CEO. “We continue to propel the growth of southwestern Pennsylvania’s life sciences economy by investing in the commercialization of promising life sciences technologies.”
The six companies that received funding are: Celsense, Inc., Glucose Sensing Technologies LLC, Falcon Genomics, Inc., Applied Computational Technologies, Separation Design Group, and ThermalTherapeutics Systems.
The PLSG’s $150,000 investment in Falcon Genomics will support research on the Cancer BioChip System (CBCS), technology that will help to treat cancer patients in a novel, personalized way.
Glucose Sensing Technologies received $100,000 to support the development and testing of a revolutionary new prototype catheter that will continually measure blood glucose levels in an Intensive Care Unit (ICU) setting.
Celsense received $100,000 to further the commercialization of Cell Sense, its flagship product, an MRI tracer agent that labels cells in culture. Separation Design Group received $100,00 for the creation of a product has the potential to revolutionize the entire portable medical oxygen market and significantly improve patient care.
Applied Computational Technologies received $150,000 to market their new product, ProACTive, which will improve radiation therapy treatment. The PLSG’s $200,000 investment in ThermalTherapeutics Systems, Inc. will help with the development of a prototype pump for delivering chemotherapy more effectively.
Source: Lynn Brusco, PLSG